Orteronel
- Generic Name
- Orteronel
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H17N3O2
- CAS Number
- 566939-85-3
- Unique Ingredient Identifier
- UE5K2FNS92
- Background
Orteronel has been investigated for the treatment of Prostate Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)
- Conditions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Emmanuel Antonarakis, MD
- Registration Number
- NCT02054793
- Locations
- πΊπΈ
Karmanos Cancer Institute, Detroit, Michigan, United States
πΊπΈJohns Hopkins University, Baltimore, Maryland, United States
πΊπΈSibley Memorial Hospital, Washington, District of Columbia, United States
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Registration Number
- NCT02053311
- Locations
- π¨π
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
π¨πKantonsspital Luzern, Luzerne, Switzerland
π¨πKantonsspital Baden, Baden, Switzerland
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT01990209
- Locations
- πΊπΈ
Hope Cancer Center, Terre Haute, Indiana, United States
πΊπΈCancer Research Consortium of West Michigan, Grand Rapids, Michigan, United States
πΊπΈNortheast Georgia Medical Center, Gainesville, Georgia, United States
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 4
- Registration Number
- NCT01866423
- Locations
- πΊπΈ
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 47
- Registration Number
- NCT01707966
- Locations
- π¨π
Kantonspital Aarau, Aarau, Switzerland
π¨πIstituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
π¨πUniversitaetsspital Basel, Basel, Switzerland
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT01666314
- Locations
- πΊπΈ
Urology Cancer Center, PC, Omaha, Nebraska, United States
TAK-700 in Castration Resistant Prostate Cancer
- Locations
- π§πͺ
Cliniques Universitaires Saint-Luc, Brussels, Belgium
π§πͺOnze Lieve Vrouw Ziekenhuis, Aals, Belgium
π§πͺAZ Groeninge Kortrijk - Campus Vercruysselaan, Kortrijck, Belgium
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1560
- Registration Number
- NCT01193244
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1099
- Registration Number
- NCT01193257
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.